Proteomic methods for biomarker discovery and validation. Are we there yet?

Expert Review of Proteomics

Volumn 12, Issue 4, 2015, Pages 329-331

  Hathout, Yetrib ^a  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

antibody bead arrays; biomarkers; biomarkers validation; proteomics; SomaScan; targeted mass spectrometry

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; PROTEIN; PROTEOME;

ANALYTIC METHOD; BODY FLUID; DIAGNOSIS; FRACTIONATION; MASS SPECTROMETRY; METABOLITE; PHARMACODYNAMICS; PLASMA; PROTEOMICS; REVIEW; SERUM; VALIDATION STUDY; LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY;

BIOMARKERS; CHROMATOGRAPHY, LIQUID; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 84937212119     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2015.1064771     Document Type: Review

References (17)

1. Bystrom S, Ayoglu B, Haggmark A, et al. Affinity proteomic profiling of plasma, cerebrospinal fluid, and brain tissue within multiple sclerosis. J Proteome Res 2014; 13(11):4607-19
2. Hathout Y, Marathi RL, Rayavarapu S, et al. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. Hum Mol Genet 2014; 23(24):6458-69
3. Mehan MR, Williams SA, Siegfried JM, et al. Validation of a blood protein signature for non-small cell lung cancer. Clin Proteomics 2014;11(1):32
4. Quon BS, Dai DL, Hollander Z, et al. Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry. Thorax 2015. [Epub ahead of print]
5. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1(11):845-67
6. Pernemalm M, Lehtio J. Mass spectrometry-based plasma proteomics: state of the art and future outlook. Expert Rev Proteomics 2014;11(4):431-48
7. Ayoglu B, Haggmark A, Neiman M, et al. Systematic antibody and antigen-based proteomic profiling with microarrays. Expert Rev Mol Diagn 2011;11(2):219-34
8. Gold L, Walker JJ, Wilcox SK, Williams S. Advances in human proteomics at high scale with the SOMAscan proteomics platform. N Biotechnol 2011;29(5):543-9
9. Tabb DL, Vega-Montoto L, Rudnick PA, et al. Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res 2010;9(2):761-76
10. Jaffe JD, Keshishian H, Chang B, et al. Accurate inclusion mass screening: A bridge from unbiased discovery to targeted assay development for biomarker verification. Mol Cell Proteomics 2008;7(10):1952-62
11. Marx V. Targeted proteomics. Nat Methods 2013;10(1):19-22
12. Carr SA, Abbatiello SE, Ackermann BL, et al. Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics 2014;13(3):907-17
13. Harlan R, Zhang H. Targeted proteomics: A bridge between discovery and validation. Expert Rev Proteomics 2014;11(6):657-61
14. Selevsek N, Chang CY, Gillet LC, et al. Reproducible and Consistent Quantification of the Saccharomyces cerevisiae Proteome by SWATH-mass spectrometry. Mol Cell Proteomics 2015;14(3):739-49
15. Lollo B, Steele F, Gold L. Beyond antibodies: new affinity reagents to unlock the proteome. Proteomics 2014;14(6): 638-44
16. Addona TA, Abbatiello SE, Schilling B, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009;27(7): 633-41
17. Brown KJ, Marathi R, Fiorillo AA, et al. Accurate quantitation of dystrophin protein in human skeletal muscle using mass spectrometry. J Bioanal Biomed 2013; (Suppl 7)